ERBB2 and breast cancer: Breast cancers with low human epidermal growth factor receptor 2 (HER2) expression, classified as an immunohistochemistry (IHC) score of 1+ or 2+ without gene amplification, have recently drawn increased interest due to the emergence of novel anti-HER2 therapies.